A Comparison between Two Type-2 Diabetes Therapeutic Agents: Once-Weekly Dulaglutide Versus Daily Liraglutide

DOI

Bibliographic Information

Other Title
  • 2型糖尿病治療薬の週1回製剤デュラグルチドと連日製剤リラグルチドにおける検査所見の比較

Search this article

Abstract

Controlling blood glucose levels is important to prevent the occurrence of type 2 diabetes complications. Recently, GLP-1 receptor agonists have been recommended in major guidelines for the treatment of diabetes. Several studies on GLP-1 receptor agonists have been conducted; these drugs are expected to exhibit not only an improvement in blood glucose levels but also in lipid levels, as well as abnormal liver and kidney function tests. GLP-1 receptor agonists are administered as once-weekly long-acting or daily short-acting preparations. Although better medication adherence has been reported with the once-weekly administration, there has been no report on the comparison of their therapeutic outcomes. Therefore, we performed a comparative analysis of changes in biochemical parameters following once-weekly dulaglutide (the most prescribed GLP-1 receptor agonist) and daily liraglutide. In this retrospective study, values of eight parameters (HbA1c, LDL-C, HDL-C, triglycerides, AST, ALT, γ-GTP, and eGFR) were extracted from medical records, and differences in these values at the initiation of administration and 6 months after the initiation were assessed. The results showed a significant decrease in HbA1c at 6 months in both dulaglutide and liraglutide groups. There was also a significant decrease in triglycerides in the dulaglutide group. Thus, dulaglutide and liraglutide are both effective at controlling blood glucose levels, although dulaglutide also improves lipid levels. These findings suggest that the once-weekly administration is more useful for diabetes treatment than the daily administration.

Journal

  • Applied Therapeutics

    Applied Therapeutics 16 (0), 17-24, 2021

    Japanese Society for Applied Therapeutics

Keywords

Details 詳細情報について

Report a problem

Back to top